Research digest / aging-decline lens
NAD and aging: why tissue NAD+ declines over time.
Less about failing production, more about rising consumption — the CD38 and senescence story, logged to source.
The short version
Here is the NAD and aging story in plain terms. NAD+ (the fuel-handling helper molecule every cell needs) declines in tissues as we age. The surprising part is why: it is less that cells stop making NAD+ and more that they start burning through it faster, because a consuming enzyme called CD38 climbs with age and inflammation. That decline has been linked, across many model organisms, to flagging metabolism. What has not been shown is that topping NAD+ back up reverses human aging. This page reports the decline, its mechanism, and the honest limits of what restoring NAD+ has been proven to do.
The decline is real and broadly observed
Tissue NAD+ falls with age, and the foundational review of NAD+ in aging frames this decline as a recurring feature across yeast, worms, mice and humans, linked to metabolic dysfunction and disease susceptibility [5]. The landmark Science review likewise describes cellular NAD+ concentrations as changing during aging, positioning that change as a modulator of health span and life span [8]. This is the well-supported half of the story: across model organisms, lower NAD+ tracks with worse metabolic resilience. A 2025 review adds the necessary caveat — that age-related NAD+ decline has been observed consistently in only a limited number of human studies, and that tissue-level human data remain sparse [14].
The CD38 NAD-consuming enzyme drives much of the fall
The mechanistic key is consumption, not just synthesis. CD38 is the principal NAD+-consuming enzyme whose activity rises with age, and it dictates the age-related NAD+ decline through a SIRT3-dependent mechanism: CD38-knockout mice are protected against the fall in tissue NAD+ and preserve SIRT3 activity, mitochondrial function and metabolic health into old age [2]. As an NADase (NAD glycohydrolase), CD38 hydrolyzes NAD+ to generate the second messenger cADPR and thereby limits the NAD+ left for sirtuins, PARPs and ARTs [11]. So the CD38 NAD-consuming enzyme functions as an age-related drain on the shared pool — which is why its biology has become central to explaining why NAD+ declines, and why simply consuming less (genetically, in mice) preserves NAD+ as effectively as making more [2].
This reframes the whole problem. If the decline were purely a synthesis failure, the fix would be to make more NAD+; but the CD38 data show a large part of the fall is over-consumption by an enzyme that climbs with age and inflammation [2][11]. That is why the field studies both levers — feeding the pool with precursors and dampening the drain — rather than assuming production is the only dial. It also explains why CD38 has drawn interest as a target in its own right: lowering an age-rising NADase is, in principle, a different route to the same endpoint as supplementing a precursor [2].
A senescence feedback loop
Aging tissue accumulates senescent cells — cells that have stopped dividing but stay metabolically active — and they feed the NAD+ drain. NAD+ metabolism participates in regulating senescence, and senescent cells increase CD38 expression via the senescence-associated secretory phenotype (SASP), the cocktail of inflammatory factors they secrete — creating a feedback loop that further depletes tissue NAD+ during aging [15]. The NAMPT–NAD+ axis sits inside this loop on the production side, governing the proinflammatory SASP itself through an HMGA–NAMPT–NAD+ route that activates NF-κB, which is why a mechanistic study cautions that NAD+ augmentation should be applied with precision in aging populations rather than blanket-maximized [6]. The picture, then, is a self-reinforcing cycle: senescence raises CD38, CD38 lowers NAD+, and lower NAD+ stresses the maintenance enzymes that might otherwise keep the system in check [15][2]. It is also a caution against assuming that flooding the system with NAD+ is uniformly good — the same NAMPT–NAD+ axis that refills the pool also helps drive the inflammatory secretion of senescent cells, so the biology resists a one-directional "more is better" reading [6].
What restoring NAD+ has — and has not — been shown to do
Restoring the NAD+ pool with precursors is the obvious idea, and it works at the level of blood chemistry: oral NR and NMN reliably raise whole-blood NAD+ in humans [4][3]. Some functional readouts have moved — muscle insulin sensitivity on NMN [1], walking distance in a multicenter NMN trial [3]. But the leap to "reversing aging" is not supported: no human trial cited here shows NAD+ precursors reverse aging or extend human lifespan, and the 2025 review concluded human efficacy for hard clinical endpoints remains limited, urging more clinical study rather than rodent extrapolation [14]. Tissue NAD+ falls and the consuming enzyme CD38 rises with age — both well documented [2][5] — but "NAD+ makes you young again" is a claim the literature does not make, and neither does this digest. For the route-by-route and safety distinctions, the frequently asked questions about NAD+ cover oral versus IV, daily-use tolerability, and what the injectable evidence does and does not show.